Newsfeeds - Spark Newswire

3 minute read

Homology Medicines Announces Presentations On HMI-203 Investigation Gene Therapy For Hunter Syndrome And Broad Applicability Of AAVHSC Platform For Lysosomal Storage Disorders At The 18th Annual WORLDSymposium Meeting

Today, 6:22 PM

Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today multiple presentations on HMI-203 gene therapy candidate for the treatment of Hunter syndrome (MPS II), which is being evaluated

FIXX

1 minute read

FDA
News

Homology Medicines Sponsored Study Titled ‘Safety and Efficacy of HMI-103, a Gene Editing Development Candidate in Adults With Classical PKU Due to PAH Deficiency’ Posted To Clinical Trials Website; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 6:22 PM

https://clinicaltrials.gov/ct2/show/NCT05222178

FIXX

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 6:22 PM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

4 minute read

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal

By Shanthi Rexaline

Today, 6:22 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ATRA

4 minute read

Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU

By Benzinga Newsdesk

Today, 6:22 PM

- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in Ongoing pheNIX Trial of

FIXX

1 minute read

Homology Medicines Q2 EPS $(0.54) Up From $(0.78) YoY, Sales $2.19M Up From $567.00K YoY

By Benzinga Newsdesk

Today, 6:22 PM

Homology Medicines (NASDAQ:FIXX) reported quarterly losses of $(0.54) per share. This is a 30.77 percent increase over losses of $(0.78) per share from the same period last year. The company reported $2.19 million in

FIXX